Barco introduced two medical-grade reviewing and conferencing projection systems Sunday at the RSNA meeting, adding to its line of large-screen imaging displays.
Barco introduced two medical-grade reviewing and conferencing projection systems Sunday at the RSNA meeting, adding to its line of large-screen imaging displays.
DICOM Theater Lite, a lightweight portable system, provides 1400 x 1050-pixel Super XGA+ resolution, 2000:1 contrast, 2000-lumen light output, and silent operation. Fully compliant with DICOM quality standards for image accuracy, Theater Lite can be connected to PACS workstations seamlessly via the BarcoMed display controller.
DICOM Theater Pro, the company's premier medical projection system, can display images from several sources using a single projector. It features an MGP 15 projector, a dedicated BarcoMed display controller, MediCal Pro QA software, and Barco's I-Guard sensors. Because of its integrated smart dual lamp design and high-resolution Poly-SI LCT technology, Theater Pro projects images with a 4500-lumen brightness.
MediCal Pro QA works with commercially available sensors as well as the I-Guard to maintain conformity and consistency of single color, gray-scale, CRT, or liquid crystal displays. The I-Guard feature stabilizes the projection of continuous images and adds DICOM compatibility.
All DICOM Theater projection systems are suitable for use with PACS as well as other source images, including computer data, endoscopy, and ultrasound.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.